Follow Us:

Press releases

7 December 2018
Regulatory
Handelsbanken Fonder and AP4 buy shares in CELLINK from the founders Handelsbanken Fonder and AP4 buy shares in CELLINK from the founders
5 December 2018 CELLINK and Prellis Biologics Inc. sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing CELLINK and Prellis Biologics Inc. sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing
4 December 2018
Regulatory
CELLINK announces collaboration with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discovery CELLINK announces collaboration with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discovery
30 November 2018
Regulatory
CELLINK has entered into an agreement to acquire the Biodispensing company Dispendix GmbH CELLINK has entered into an agreement to acquire the Biodispensing company Dispendix GmbH
14 November 2018
Regulatory
CELLINK publishes annual report for 2017/2018 CELLINK publishes annual report for 2017/2018
6 November 2018 CELLINK IS LAUNCHING NEW BIOINKS CELLINK IS LAUNCHING NEW BIOINKS
24 October 2018
Regulatory
Interim financial report 4 for the period 1st of June – 31st of August and the report for the full fiscal year Interim financial report 4 for the period 1st of June – 31st of August and the report for the full fiscal year
17 October 2018 CELLINK IS LAUNCHING NEW BIOINKS CELLINK IS LAUNCHING NEW BIOINKS
3 October 2018 CELLINK and partners have been granted project financing from EU totaling €5,700,000 for the Giotto project. CELLINKs portion of the grant is €300,000 CELLINK and partners have been granted project financing from EU totaling €5,700,000 for the Giotto project. CELLINKs portion of the grant is €300,000
11 September 2018 CELLINK brings on world distinguished scientist Dr. Mina J. Bisell to advisory board CELLINK brings on world distinguished scientist Dr. Mina J. Bisell to advisory board
4 September 2018 CELLINK’s bioink and bioprinters are being used in several progressive research areas CELLINK’s bioink and bioprinters are being used in several progressive research areas
27 August 2018 CELLINK launches new bioink series based on laminins CELLINK launches new bioink series based on laminins
16 July 2018
Regulatory
CELLINK to receive €2.5 million grant from EU for the development and commercializing project “TumorPrint “ CELLINK to receive €2.5 million grant from EU for the development and commercializing project “TumorPrint “
11 July 2018
Regulatory
Quarterly report 3 for the period 1st of March – 31st of May and for the first 9 months Quarterly report 3 for the period 1st of March – 31st of May and for the first 9 months
4 July 2018 CELLINK Collaborator Enables Controlled Cell Formation CELLINK Collaborator Enables Controlled Cell Formation
4 June 2018
Regulatory
CELLINK has completed a directed share issue of approximately SEK 100 million CELLINK has completed a directed share issue of approximately SEK 100 million
4 June 2018
Regulatory
CELLINK intends to make a directed share issue of Class B shares CELLINK intends to make a directed share issue of Class B shares
1 June 2018 CELLINK customer and technology user at Newcastle University 3D-Bioprinted first human corneas in cutting edge breakthrough CELLINK customer and technology user at Newcastle University 3D-Bioprinted first human corneas in cutting edge breakthrough
11 May 2018
Regulatory
CELLINK receives 3.5 MSEK order from distributor CELLINK receives 3.5 MSEK order from distributor
4 May 2018 CELLINK Collaborator 3D-Bioprinted Human Heart Valve Disease Models Using Nanoindentation-Based Biomechanics CELLINK Collaborator 3D-Bioprinted Human Heart Valve Disease Models Using Nanoindentation-Based Biomechanics
2 May 2018 CELLINK launches new educational platform for Bioprinting: CELLINK GO - Made to Revolutionize Education CELLINK launches new educational platform for Bioprinting: CELLINK GO - Made to Revolutionize Education
23 April 2018 CELLINK appoints Carnegie Investment Bank AB (publ) as financial adviser CELLINK appoints Carnegie Investment Bank AB (publ) as financial adviser
13 April 2018 CELLINK releases 7 new Bioinks, 3 new Kits, and standardized GelMA, to Enable the Bioprinting of Multifaceted Vascularized Constructs such as Skin CELLINK releases 7 new Bioinks, 3 new Kits, and standardized GelMA, to Enable the Bioprinting of Multifaceted Vascularized Constructs such as Skin
13 April 2018 CELLINK lanserar 7 nya Biobläck, 3 nya kits med GelMA samt möjliggör 3D-Bioprinting av mångfasetterade vaskulära nätverk CELLINK lanserar 7 nya Biobläck, 3 nya kits med GelMA samt möjliggör 3D-Bioprinting av mångfasetterade vaskulära nätverk
19 March 2018 CELLINK publishes article about bioink together with world renowned scientists CELLINK publishes article about bioink together with world renowned scientists
8 February 2018 CELLINK launches the CELLINK X Bioink Series CELLINK launches the CELLINK X Bioink Series
1 February 2018 CELLINK opens office at Kyoto University in Japan CELLINK opens office at Kyoto University in Japan
17 January 2018 CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub
17 January 2018
Regulatory
Quarterly report 1 for the period 1st of September – 30th of November Quarterly report 1 for the period 1st of September – 30th of November
8 January 2018 CELLINK signs collaboration agreement with CTIBIOTECH for Bioprinting of patient-specific cancer tumors CELLINK signs collaboration agreement with CTIBIOTECH for Bioprinting of patient-specific cancer tumors
20 December 2017
Regulatory
Communication from the Annual General Meeting on 14 December Communication from the Annual General Meeting on 14 December
27 November 2017 CELLINK has been granted project funding from Horizon 2020 CELLINK has been granted project funding from Horizon 2020
15 November 2017 CELLINK enters a collaborative research program with Takara Bio CELLINK enters a collaborative research program with Takara Bio
19 October 2017
Regulatory
End of the year report for the period 1 of September – 31st of August and Quarterly report 4 End of the year report for the period 1 of September – 31st of August and Quarterly report 4
6 October 2017
Regulatory
CELLINK closes a directed share issue of SEK 30 million to Handelsbanken Fonder CELLINK closes a directed share issue of SEK 30 million to Handelsbanken Fonder
27 September 2017 CELLINK signs collaboration agreement with MIT CELLINK signs collaboration agreement with MIT
25 September 2017 CELLINK receives design patent CELLINK receives design patent
14 August 2017 Several new publications with CELLINKs technology Several new publications with CELLINKs technology
19 July 2017
Regulatory
CELLINK publishes quarterly report for the third quarter CELLINK publishes quarterly report for the third quarter
12 July 2017
Regulatory
CELLINK completes a directed share issue of 30 million SEK CELLINK completes a directed share issue of 30 million SEK
10 July 2017
Regulatory
CELLINK signs distribution agreement with Thermo Fisher Scientific ANZ CELLINK signs distribution agreement with Thermo Fisher Scientific ANZ
9 June 2017
Regulatory
CELLINK receives orders for products in conjunction with expansion CELLINK receives orders for products in conjunction with expansion
23 May 2017 CELLINK speaks of breakthrough in Bioprinting at an international conference CELLINK speaks of breakthrough in Bioprinting at an international conference
17 March 2017
Regulatory
CELLINK AB has appointed an Advisory Board CELLINK AB has appointed an Advisory Board
12 January 2017
Regulatory
CELLINK launches BIO X, a new 3D-Bioprinter CELLINK launches BIO X, a new 3D-Bioprinter
7 December 2016 CELLINK launches BioVerse - a platform for 3D-Bioprinting CELLINK launches BioVerse - a platform for 3D-Bioprinting
Show more

Ownership information

Owner A-stock B-stock Ownership Voting Right
Gatenholm, Erik 207 031 2 580 009 33.5% 39.8%
Martinez Avila, Hector Daniel 136 719 1 712 821 22.2% 26.3%
Fore C Investment Holding AB 724 808 8.7% 6.2%
Handelsbanken Fonder 571 678 6.9% 4.9%
Carl Bennet AB 396 599 4.8% 3.4%
Fjärde AP-Fonden 300 000 3,6% 2,6%
Danielsson, Gusten 15 625 215 485 2.8% 3.2%
Svanberg, Jockum 15 625 192 408 2.5% 3.0%
Dinkelspiel, Claes 205 285 2.5% 1.8%
Nordlund, Jonas 144 644 1.7% 1.2%
Other owners 904 702 10.9% 7.7%
Total 375 000 7 948 439 100.0% 100.0%

Management

Erik Gatenholm
CEO
Hector Martinez
CTO
Gusten Danielsson
CFO

Board of directors

Göran Nordlund
Chairman of the board
Göran Norlund is a contractor, private investor and board member. Since 2002, he has worked with a well-developed network of entrepreneurs to effectively invest in and build value in entrepreneurial companies. Several of these companies have been able to show very high profitable growth during these years and have also provided a good return on the way to all its shareholders.
Erik Gatenholm
Board Member
Erik Gatenholm is a serial entrepreneur and CEO/Co-Founder of CELLINK. The entrepreneurial and biotech world fascinated Gatenholm from an early age. Gatenholm started his first biomedical device company known as BC Genesis at age 18 in Blacksburg, Virginia in 2008 to commercialize a licensed university technology. BC Genesis focused on developing cellulose based medical implants for applications such as meniscus/cartilage repair as well as surgical meshes. Throughout his undergraduate studies in Management at Virginia Tech University, Gatenholm continued his work with BC Genesis and began brainstorming for his future. In 2014 he moved to Sweden to complete his MBA at Gothenburg University, focusing on the commercialization of biotechnology startups. After meeting Dr. Hector Martinez at Chalmers University in late 2014, they begun to work to commercialize the biomaterial innovation behind CELLINK.
Hector Martinez
Board Member
Hector Martinez is the CTO/Co-Founder of CELLINK. Martinez has contributed his knowledge of tissue engineering and the 3D Bioprinting field to drive CELLINK to where it is today. Martinez received his doctorate in Cartilage Tissue Engineering from Chalmers University of Technology and has 7 years of experience in biomaterials, tissue engineering and 3D bioprinting technologies. He obtained a B.Sc. in Mechanical Engineering from the University of Texas at Arlington and M.Sc. in Biomedical Engineering from Chalmers University of Technology in Sweden.
Bengt Sjöholm
Board Member
Bengt Sjöholm is a former football player and Swedish champion in Halmstad's BK and also former chairman of the same club. Sjöholm has been CEO of several Swedish companies, including Tylö AB, where he was CEO between 2004 and 2009. During the 1990s, Sjöholm was acting as CEO of a subsidiary of Getinge AB.
Klementina Österberg
Board Member
Klementina Östberg is CEO of GU Ventures. She is an expert in finance, business and company development with experience of company board work, investments, protection and commercialisation of IPR and marketing. Direct experience with management, business development and venture capital. Interested in early-stage startups as well as creating partnerships with the academia, healthcare and industry.
Artur Aira
Board Member
Arthur Aira is a medical tech engineer and MBA by training. Aira received his engineering and med tech degree at Chalmers University. Prior to his role as Executive Vice President at AddLife, Aira worked various leadership roles for the past 20 years at Organon Teknika, bioMerieux and AddTech Life Science where he served as both the Vice President and President/CEO.
Ingela Hallberg
Board Member
Ingela Hallberg is doctor by training. She received her medical degree at Gothenburg University. Hallberg started her career as a physician at Sahlgrenska University Hospital in Gothenburg. After several years at Sahlgrenska, Hallberg then spent the next 20 years working in leadership roles for various pharma industry leaders such as Bayer Healthcare, Lundbeck, Quintiles and Merck.
Andreas Albertsson
Deputy Board Member
Andreas Albertsson is a business developer who likes to create business opportunities based on innovations or know-how. Have for the last 10 years worked hands on with commercialization of innovations, entrepreneurship, management, venture creation, venture capital and regional development.

Certified Advisor

Erik Penser Bank AB tel. +46 8 463 80 00

First North

Nasdaq First North is an alternative market, operated by the different exchanges within Nasdaq OMX. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market. All companies whose shares are traded on First North have a certified adviser who monitors the company’s compliance with First North’s rules regarding the disclosure of information to the market and investors.

Videos

Finwire TV visits CELLINK
The future of Medicine

Calendar

24-October-2018         Interim Repor June – August 2017 and end of year report
14-November-2018         Annual report
13-December-2018         Annual general meeting

CELLINK bakom kulisserna

Följ vår resa mot framtidens medicin.

På denna sida så finner ni finansiella rapporter, nyheter, och annan information om CELLINK. Prenumerera på vår sida för att ta del av de senaste uppdateringarna om CELLINK.

Pressmeddelanden

7 December 2018
Regulatory
Handelsbanken Fonder och AP4 köper aktier i CELLINK från grundarna Handelsbanken Fonder och AP4 köper aktier i CELLINK från grundarna
5 December 2018 CELLINK och Prellis Biologics Inc. tecknar partnerskap för att kommersialisera holografisk bioprintingteknik med hög upplösning för mikroutskrift CELLINK och Prellis Biologics Inc. tecknar partnerskap för att kommersialisera holografisk bioprintingteknik med hög upplösning för mikroutskrift
4 December 2018
Regulatory
CELLINK tillkännager samarbete med MedImmune med syfte att utnyttja CELLINKs 3D-bioprinting-teknik för nya läkemedelsupptäckter CELLINK tillkännager samarbete med MedImmune med syfte att utnyttja CELLINKs 3D-bioprinting-teknik för nya läkemedelsupptäckter
30 November 2018
Regulatory
CELLINK ingår avtal om förvärv av biodispenseringsbolaget Dispendix GmbH CELLINK ingår avtal om förvärv av biodispenseringsbolaget Dispendix GmbH
14 November 2018
Regulatory
CELLINK publicerar årsredovisning för 2017/2018 CELLINK publicerar årsredovisning för 2017/2018
14 November 2018
Regulatory
Kallelse till årsstämma i CELLINK AB Kallelse till årsstämma i CELLINK AB
6 November 2018 CELLINK LANSERAR NYA BIOBLÄCK CELLINK LANSERAR NYA BIOBLÄCK
24 October 2018
Regulatory
CELLINK offentliggör Bokslutskommuniké och rapport för 4:e kvartalet CELLINK offentliggör Bokslutskommuniké och rapport för 4:e kvartalet
17 October 2018 CELLINK LANSERAR NYA BIOBLÄCK CELLINK LANSERAR NYA BIOBLÄCK
3 October 2018 CELLINK och partners har beviljats projektfinansiering om 5,700 000 EURO från EU för projektet GIOTTO. CELLINKs andel uppgår till 300 000 EURO CELLINK och partners har beviljats projektfinansiering om 5,700 000 EURO från EU för projektet GIOTTO. CELLINKs andel uppgår till 300 000 EURO
11 September 2018 CELLINK värvar den världsberömda forskaren Dr. Mina J. Bisell till sin Advisory Board CELLINK värvar den världsberömda forskaren Dr. Mina J. Bisell till sin Advisory Board
4 September 2018 CELLINK’s biobläck och bioprinters används i flera olika progressiva forskningsområden CELLINK’s biobläck och bioprinters används i flera olika progressiva forskningsområden
27 August 2018 CELLINK lanserar ny biobläck-serie baserad på lamininer CELLINK lanserar ny biobläck-serie baserad på lamininer
16 July 2018
Regulatory
CELLINK beviljades 2,5 miljoner euro i finansiering från EU för utvecklings- och kommersialiseringsprojektet "TumorPrint" CELLINK beviljades 2,5 miljoner euro i finansiering från EU för utvecklings- och kommersialiseringsprojektet
11 July 2018
Regulatory
CELLINK offentliggör kvartalsrapport för tredje kvartalet samt rapport för första 9-månaderna CELLINK offentliggör kvartalsrapport för tredje kvartalet samt rapport för första 9-månaderna
4 July 2018 CELLINK kund möjliggör kontrollerad cellformation CELLINK kund möjliggör kontrollerad cellformation
4 June 2018
Regulatory
CELLINK har genomfört en riktad nyemission om cirka 100 miljoner kronor CELLINK har genomfört en riktad nyemission om cirka 100 miljoner kronor
4 June 2018
Regulatory
CELLINK avser genomföra en riktad nyemission av aktier av serie B CELLINK avser genomföra en riktad nyemission av aktier av serie B
1 June 2018 CELLINK kund- och teknikanvändare vid Newcastle University 3D Bioprintar första mänskliga hornhinnorna i banbrytande genombrott CELLINK kund- och teknikanvändare vid Newcastle University 3D Bioprintar första mänskliga hornhinnorna i banbrytande genombrott
11 May 2018
Regulatory
CELLINK mottar order om 3,5 MSEK från distributör CELLINK mottar order om 3,5 MSEK från distributör
4 May 2018 CELLINK samarbetspartner 3D-Bioprintade Humana Hjärtvalvsjukdomsmodeller med Nanoindentationsbaserad biomekanik CELLINK samarbetspartner 3D-Bioprintade Humana Hjärtvalvsjukdomsmodeller med Nanoindentationsbaserad biomekanik
3 May 2018
Regulatory
CELLINK AB byter Certified Adviser till Erik Penser Bank AB CELLINK AB byter Certified Adviser till Erik Penser Bank AB
2 May 2018 CELLINK lanserar ny pedagogisk plattform för bioprinting: CELLINK GO – Framtagen för att Revolutionera utbildningen CELLINK lanserar ny pedagogisk plattform för bioprinting: CELLINK GO – Framtagen för att Revolutionera utbildningen
23 April 2018 CELLINK utser Carnegie Investment Bank AB (publ) till finansiell rådgivare CELLINK utser Carnegie Investment Bank AB (publ) till finansiell rådgivare
19 April 2018 CELLINK ingår partnerskap med ARMI BioFab USA, UNH Manchester för regenerativtillverkningsevenemang CELLINK ingår partnerskap med ARMI BioFab USA, UNH Manchester för regenerativtillverkningsevenemang
11 April 2018
Regulatory
CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat
9 April 2018 CELLINK WINS RED DOT AWARD FOR BIO X CELLINK WINS RED DOT AWARD FOR BIO X
9 April 2018 CELLINK VINNER RED DOT AWARD FÖR BIO X CELLINK VINNER RED DOT AWARD FÖR BIO X
19 March 2018 CELLINK publicerar artikel om biobläck tillsammans med världsledande forskare CELLINK publicerar artikel om biobläck tillsammans med världsledande forskare
8 February 2018 CELLINK lanserar CELLINK X Bioinks CELLINK lanserar CELLINK X Bioinks
1 February 2018 CELLINK öppnar kontor på Kyoto University i Japan CELLINK öppnar kontor på Kyoto University i Japan
17 January 2018 CELLINK etablerar ett forsknings- och utvecklingslaboratorie i AstraZenecas BioVentureHub CELLINK etablerar ett forsknings- och utvecklingslaboratorie i AstraZenecas BioVentureHub
17 January 2018
Regulatory
Kvartalsrapport 1 (Q1) för 1 september 2017 – 30 november 2017 Kvartalsrapport 1 (Q1) för 1 september 2017 – 30 november 2017
8 January 2018 CELLINK ingår ett samarbetsavtal med CTIBIOTECH för att skriva ut patientspecifika cancertumörer CELLINK ingår ett samarbetsavtal med CTIBIOTECH för att skriva ut patientspecifika cancertumörer
20 December 2017
Regulatory
Kommuniké från årsstämma den 14 december Kommuniké från årsstämma den 14 december
27 November 2017 CELLINK har blivit beviljat projektfinansiering från Horizon 2020 CELLINK har blivit beviljat projektfinansiering från Horizon 2020
16 November 2017
Regulatory
Publicering av CELLINKs årsredovisning för 2016/2017 Publicering av CELLINKs årsredovisning för 2016/2017
15 November 2017 CELLINK ingår ett utvecklingssamarbete med Takara Bio CELLINK ingår ett utvecklingssamarbete med Takara Bio
15 November 2017
Regulatory
Kallelse till årsstämma i CELLINK AB Kallelse till årsstämma i CELLINK AB
19 October 2017
Regulatory
Bokslutskommuniké för 1 september 2016 – 31 augusti 2017 samt kvartalsrapport 4 Bokslutskommuniké för 1 september 2016 – 31 augusti 2017 samt kvartalsrapport 4
6 October 2017
Regulatory
CELLINK genomför riktad nyemission av B-aktier om 30 MSEK till Handelsbanken Fonder CELLINK genomför riktad nyemission av B-aktier om 30 MSEK till Handelsbanken Fonder
27 September 2017 CELLINK tecknar samarbetsavtal med MIT CELLINK tecknar samarbetsavtal med MIT
25 September 2017 CELLINK beviljas mönsterskydd CELLINK beviljas mönsterskydd
14 August 2017 Nya publikationer med CELLINKs teknologier Nya publikationer med CELLINKs teknologier
19 July 2017
Regulatory
CELLINK offentliggör kvartalsrapport för tredje kvartalet CELLINK offentliggör kvartalsrapport för tredje kvartalet
12 July 2017
Regulatory
CELLINK genomför riktad nyemission av B-aktier om 30 MSEK CELLINK genomför riktad nyemission av B-aktier om 30 MSEK
10 July 2017
Regulatory
CELLINK tecknar distributionsavtal med Thermo Fisher Scientific ANZ CELLINK tecknar distributionsavtal med Thermo Fisher Scientific ANZ
9 June 2017
Regulatory
CELLINK tar emot ordrar av produkter i samband med expansion CELLINK tar emot ordrar av produkter i samband med expansion
23 May 2017 CELLINK talar om genombrott inom Bioprintning på internationell konferens CELLINK talar om genombrott inom Bioprintning på internationell konferens
12 April 2017
Regulatory
CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat
Show more

Video

Finwire TV besöker CELLINK
Framtiden för medicin

Uppgifter om aktieägare

 

Ägare A-Aktier B-Aktier Kapitalandel Röstandel
Gatenholm, Erik 207 031 2 580 009 33.5% 39.8%
Martinez Avila, Hector Daniel 136 719 1 712 821 22.2% 26.3%
Fore C Investment Holding AB 724 808 8.7% 6.2%
Handelsbanken Fonder 571 678 6.9% 4.9%
Carl Bennet AB 396 599 4.8% 3.4%
Fjärde AP-Fonden 300 000 3,6% 2,6%
Danielsson, Gusten 15 625 215 485 2.8% 3.2%
Svanberg, Jockum 15 625 192 408 2.5% 3.0%
Dinkelspiel, Claes 205 285 2.5% 1.8%
Nordlund, Jonas 144 644 1.7% 1.2%
Other owners 904 702 10.9% 7.7%
Totalt 375 000 7 948 439 100.0% 100.0%

 

Ledningsgrupp

Erik Gatenholm
CEO
Hector Martinez
CTO
Gusten Danielsson
CFO

Styrelse

Göran Nordlund
Styrelseordförande
Erik Gatenholm
Styrelseledamot
Hector Martinez
Styrelseledamot
Bengt Sjöholm
Styrelseledamot
Klementina Österberg
Styrelseledamot
Andreas Albertsson
Suppleant

Certified Advisor

Erik Penser Bank AB tel. +46 8 463 80 00

First North

First North är en alternativ marknadsplats som drivs av de olika börserna som ingår i Nasdaq OMX. Den har inte samma juridiska status som en reglerad marknad. Bolag på First North regleras av First North regler och inte av de juridiska krav som ställs för handel på en reglerad marknad. En placering i ett bolag som handlas på First North är mer riskfylld än en placering i ett börsnoterat bolag. Alla företag vars aktier handlas på First North har en certifierad rådgivare som övervakar bolagets överensstämmelse med First Norths regler om information till marknaden och investerare.

Kalendarium

24-oktober-2018         Delårsrapport juni – augusti 2017 samt bokslutskommuniké
14-november-2018         Årsredovisning
13-december-2018         Årsstämma